Does the use of sodium zirconium cyclosilicate in dialysis patients reduce cardiovascular risk? Is this treatment appropriate?
Year: 2026
Type: article
Abstract: No direct evidence for reducing cardiovascular risk with sodium zirconium cyclosilicate in dialysis patients. It effectively manages hyperkalemia, potentially offering indirect cardiovascular benefits by enabling RAASi therapy.
Author: Tripdatabase
Language: English
Subfield: Nephrology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7236838222
